BrainXell specializes in producing high-purity, iPSC-derived human neurons, astrocytes, and microglia for research and drug discovery in central nervous system disorders. The company provides customizable cell lines in various quantities, enabling researchers to advance their studies with precise, patient-derived cellular models.
Funding
$15.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Research and drug discovery for central nervous system (CNS) disorders are often limited by the availability of high-quality, consistent human cell models. Traditional methods rely on animal models or immortalized cell lines, which may not accurately replicate the complexity of human brain cells and disease mechanisms. This can lead to inaccurate results and hinder the development of effective therapies.
Solution
BrainXell produces high-purity, induced pluripotent stem cell (iPSC)-derived human neurons, astrocytes, and microglia to advance research and drug discovery for CNS disorders. The company offers customizable cell lines derived from both publicly available and proprietary iPSC lines, including patient-derived and gene-edited options. BrainXell provides cells in quantities ranging from 25 million to 10 billion cells per batch, enabling researchers to conduct studies at their desired scale. These human cell models provide a more accurate and relevant platform for studying brain function and disease.
Target Audience
BrainXell's primary customers are researchers and drug discovery companies focused on central nervous system disorders.
Features
- iPSC-derived human neurons, astrocytes, and microglia
- Customizable cell lines from publicly available, proprietary, patient-derived, and gene-edited iPSC lines
- Batch sizes ranging from 25 million to 10 billion cells
- Stringent quality control to ensure high purity and consistency